Nocturne Acquisition Corp is a United States-based company. The Company is a shell company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The Company has no operations and has not generated revenues.

Employees

Sector

Investment Holding Companies

More about the company

Delayed Nasdaq Other stock markets 16:00:00 2024-04-03 EDT			5-day change	1st Jan Change
11.66 ^USD	-0.49%		-.--%	-

24-04-02	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
24-03-30	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI

Market Cap	60.48M 52.85M 48.88M 45.63M 85.65M 5.72B 86.28M 581M 226M 2.81B 227M 222M 9.76B	P/E 2021	-163x	P/E 2022	-78.5x
Enterprise Value	64.05M 55.97M 51.77M 48.32M 90.71M 6.05B 91.38M 615M 239M 2.98B 240M 235M 10.34B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	23.5%	Yield 2021 *	-	Yield 2022	-

24-04-02	Nocturne Acquisition Corporation(NasdaqCM:MBTC) dropped from NASDAQ Composite Index	CI
24-03-30	Cognos Therapeutics Inc. cancelled the acquisition of Nocturne Acquisition Corporation from a group of shareholders in a reverse merger transaction.	CI
24-02-07	Nocturne Acquisition Corporation Announces Management Changes	CI
24-02-05	Nocturne Acquisition Shares Jump as Stockholders' Vote on Merger With Cognos Therapeutics Postponed Further	MT
23-11-22	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
23-08-21	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-23	Nocturne Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-05-26	Nocturne Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-05-25	Nocturne Acquisition Corporation Auditor Raises 'Going Concern' Doubt	CI
23-01-03	Nocturne Acquisition in Deal to Merge With Cognos Therapeutics	MT
23-01-02	Cognos Therapeutics Inc. executed a definitive business combination agreement to acquire Nocturne Acquisition Corporation from Nocturne Sponsor, LLC, Polar Asset Management Partners Inc., Periscope Capital Inc, Sea Otter Advisors LLC and others for approximately $120 million in a reverse merger transaction.	CI
22-11-21	Nocturne Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
22-08-22	Nocturne Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

23-09-20	Chardan Engaged to Facilitate Nocturne Acquisition Corporation's Business Combination with Cognos Therapeutics, Inc., Paving the Way for NASDAQ Listing	AQ
23-05-02	NOCTURNE ACQUISITION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-04-14	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-04-06	NOCTURNE ACQUISITION CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
23-04-03	NOCTURNE ACQUISITION CORP : Regulation FD Disclosure (form 8-K)	AQ

Cognos Therapeutics Holdings, Inc. Stock

Stocks

MBTC

KYG6580S1140

Investment Holding Companies

Valuation: Cognos Therapeutics Holdings, Inc.

Latest news : Cognos Therapeutics Holdings, Inc.

Press Releases: Cognos Therapeutics Holdings, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Cognos Therapeutics Holdings, Inc.

Latest insider transactions

Shell Companies

Financials

Company Profile

Manager	Title	Age	Since
Henry Monzon CEO	Chief Executive Officer	52	2020-10-27
Ka Seng Ao DFI	Director of Finance/CFO	37	2020-10-27
Haoyu Lin PRN	Corporate Officer/Principal	37	2024-02-01

Director	Title	Age	Since
Henry Monzon CHM	Chairman	52	2020-10-27
Ka Seng Ao BRD	Director/Board Member	37	2020-10-27
Hon Keung Choi BRD	Director/Board Member	65	2021-12-15

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-02-01	Nocturne Sponsor LLC	Other	Company	3,340,000	27.9148%
21-04-13	Nocturne Sponsor LLC	Buy	Company	15,000	0.1435%
21-04-13	Nocturne Sponsor LLC	Buy	Company	15,000	0.1435%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COGNOS THERAPEUTICS HOLDINGS, INC.	-0.49%	-.--%	-.--%	+5.23%	56.65M
EINRIDE AB	-4.01%	-30.68%	-	-	996M
CENTIEL AG	+4.69%	+11.83%	+443.75%	-56.28%	860M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	-0.10%	+0.10%	-	-	643M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.19%	+0.49%	-	-	600M
CANTOR EQUITY PARTNERS IV, INC.	0.00%	0.00%	-	-	591M
CHURCHILL CAPITAL CORP XI	+0.24%	+1.27%	-	-	578M
ACC AVIATION HOLDINGS LTD.	-19.01%	+15.00%	+1,050.00%	+262.66%	574M
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	-0.45%	-1.33%	-	-	552M
Average	-2.41%	-0.16%	+497.92%	+70.54%	605.48M
Weighted average by Cap.	-2.43%	-1.90%	+660.25%	+68.83%

	2021	2022
Net sales	-	-
Net income	-710K -621K -574K -536K -1.01M -67.11M -1.01M -6.82M -2.65M -33M -2.67M -2.61M -115M	-1.21M -1.06M -977K -912K -1.71M -114M -1.72M -11.61M -4.52M -56.14M -4.54M -4.44M -195M
Net Debt	-385K -336K -311K -290K -545K -36.34M -549K -3.69M -1.44M -17.87M -1.44M -1.41M -62.06M	3.57M 3.12M 2.89M 2.7M 5.06M 338M 5.1M 34.31M 13.35M 166M 13.41M 13.12M 577M

3 years	9.45	13.98
5 years	9.45	13.98
10 years	9.45	13.98